Interim Results

AI SummaryClose X

N4 Pharma PLC reported an operating loss of £470,216 for the six months ended June 30, 2025, a reduction from £491,705 in the prior year. The company's cash position remained strong at £1,727,543, compared to £1,204,946 in the previous year, boosted by a successful placing in April 2025 that raised £1,750,000 in gross proceeds. Basic and diluted loss per share was (0.09p) compared to (0.16p) the previous year. The company issued 87,500,000 warrants at an exercise price of 0.4p per warrant as part of the placing in April 2025. Total equity increased to £1,767,289 from £651,402 at the end of 2024.

Disclaimer*

UK 100

Latest directors dealings